BeOne Medicines Ltd. American Depositary Shares — Chart, Price & News (NASDAQ:ONC)

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Market Capitalization 447.1135 B
Employee 11 K
Founded 2010
CEO John Vincent OylerJohn Vincent Oyler
Website www.beonemedicines.com
Headquarter N/A
FIGI BBG00B6WF7T5
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

447.11 B Market capitalization

Price to earnings ratio

1 599

Price to sales ratio

—

Dividends per share

—

Dividend yield %

—

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.